Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.

[1]  J. Lipton,et al.  Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? , 2005, Bone Marrow Transplantation.

[2]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[3]  M. L. Beau,et al.  Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes , 2005, Bone Marrow Transplantation.

[4]  F. Šorm,et al.  5-Azacytidine, a new, highly effective cancerostatic , 1964, Experientia.

[5]  R. Shadduck,et al.  AML Induction Therapy with Outpatient Azacitidine. , 2004 .

[6]  E. Eisenhauer,et al.  DNA methyltransferase inhibitors-state of the art. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Schiffer,et al.  Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. , 1993, Leukemia.

[10]  B. Leyland-Jones,et al.  Azacitidine: 10 years later. , 1987, Cancer treatment reports.

[11]  R. Gale,et al.  Acute myelogenous leukemia: recent advances in therapy , 1987 .